Member Info for Fruitsnveg

I'm not sure that's totally correct? We know CFDs have been mentioned in some previous Polyg RNSs. I can't remember the proportion. Are the sale of those notifiable? Will we know if they quietly offload some? What do the regulations say? It's something I've been meaning to look into so thanks for the reminder Doc83. If someone here knows, please do share.

"I assume it will be very difficult to reach a good return on their investment given their average." I doubt that. We are talking about a hedge fund full of clever analysts and market strategists. They don't make a punt, they invest based on good research. All we here can do is best guess what their average is, as no one here can say with certainty as no one here works for Polyg, ...I assume? According to Polyg's annual report, they managed to renegotiate their borrowing at a pretty attractive rate, especially given current market conditions. That tells me that the investments our hedge fund friends hold are not viewed by their lender as disastrously high risk. Their liabilities, of which SNG holding is one, has not scared the horses. That is why they got an attractive market rate. If a writing down of their investment in Synairgen was on the cards, I doubt their lender would have extended their borrowing at such an attractive rate. As always my opinion, DYOR and GLA.

As Ghia astutely remarked here recently "I don’t understand the desire to control the dialogue on the boards". It seems '15p' is the new crew cue.

Also from this poster:
"I will bash the company repeatedly following Ph3 disaster and if someone wants to pay me to do so then at least I might make some money out of the company."

Green bin it.

Andybetrippin, lol.

Prof. Anita Simonds is one of 2 'discussants' for this session. [For info, discussants are responsible for providing professional and constructive criticism and raising issues for broader consideration during the session as a way to connect the papers presented. A discussant may draw upon his or her expertise or views in commenting on papers or presentations.] Synairgen's study has been selected as one such clinical trial results paper for this session so it must be viewed as "important
and very late-breaking clinical trial data" which is a pre-requisite according to the session header info on page 200. I note Professor Anita Simonds is a Consultant in Respiratory Medicine with a research and clinical interest in sleep disordered breathing, and acute and chronic respiratory failure in adults and children. Professor Simonds’ team have performed randomised controlled trials of the timing of initiation of non-invasive ventilation, and of a variety of ventilatory modes. This work has contributed to numerous clinical guidelines and standards of care.
This should be an interesting session.

Will it be a Costa Coffee though Dunk?

Gunto, that date & time stamp is on all speaker pages. Thy all say 25/Aug/22 18:45 GMT.

I'm not sure I follow Ghia. What is your point? Do you mean that the conference is going to be viewed as uninteresting because 4 titles have yet to be confirmed?

Ghia,

"What’s more interesting to me is the title of Marsdens presentation at the other conference is yet to be released. Read into that what you will. " What are you inferring Ghia?
Marsden is not the only speaker whose speech title is pending. Here are some others:

- Sept 7th 11.20am Session title to be announced (Adaptive Technologies)
- Sept 8th 9:00am Keynote Address: Session title to be announced
- Sept 8th 11.40am Panel: Session title to be announced

"If you want to be bullish you might also suggest that Richard Marsden has taken this little gig as he is in the US in early September anyway, to fry a much bigger fish ."

Which fish would this be Doc.daneeka?

I'm happy with the current CEO Richard Marsden and will remain invested whilst he is at the helm. As you put it so eloquently TLW, "His scientific presentations are clear and concise. I am buoyed that he is presenting at the next significant conference." I do concur.
As for it being " high time to bring these senior executives, all of whom have a proven track record, to the fore. We have heard little from them to date", I am of the opinion that they are best kept working hard yet quietly behind the scenes. There is much to be done and running a tight ship free of distractions is to be commended. We are in a time-critical phase for the company - the less distractions the better IMHO.

That and a host of others hopefully WPA5.

The title has yet to be released, as is the same for some other speakers at the same conference. Communicate when you have something to say, not before, IMHO.

Maybe Org is Stacey, or Stacey s Org?

Now that would be something!

What's your view on it Ghia? Do you think it will affect us (Synairgen) in any way, or just something the whole industry will have to grapple with?

"You could argue if you really wanted to get the messaging right you stump up the money and get a team of writers with real pedigree to work on a contract basis." You could argue that Ghia but IMO it would not be an intelligent or acceptable argument for the majority of shareholders here who have their eyes on the balance sheet. And they do, as we are reminded very regularly here. A team of expensive contract resources vs a cheaper in-house hire is not cost-effective in the long-term. I think the company are focussed on the long-term messaging, they must be if they are willing to offer a pensionable role on full benefits. Furthermore, by outsourcing such work you don't retain knowledge within the company. At a certain point you want to be retaining and building upon knowledge within a small biotech set for growth, breaking reliance on 3rd parties where possible. Perhaps we are approaching that point, hence the timing of this hire.....

Just re-reading the job role wording, it's interesting that they ask for "A strong track record in publication planning and delivery, with a preference for expertise in Pulmonology, Infectious Disease, and/or Critical Care is strongly preferred". As opposed say to the narrower filed of Covid-19. Some recent job adverts online ask for "MRNA/ Covid 19" for example. They could have been more targeted in their wording, but they went for a broad reach with "Pulmonology, Infectious Disease, and/or Critical Care". That should also tell us something and is further proof perhaps that this writer is not just being hired to write up a quick few outputs on A2 data.

The role is "publication planning and delivery". It will be more than A2 write up OMO Doc.Daneeka. if it were just that, witch such focus now on every £ spent, the company would simply engage a contract resource. But they have made the decision (not lightly I imagine) to approve spend on a full-time pensionable resource. This shows me the role, coming at this particular time, is probably pivotal, not not just some BAU 'churn' role.

They are running an outpatient home-based trial, but they are not "switching to monkeypox". Platinum and Recovery are 2 separate trials.